Aclarion's Nociscan Solution To Play Key Role In LIFEHAB Trial Evaluating The Diagnosis And Treatment Of Chronic Low Back Pain
Portfolio Pulse from Benzinga Newsdesk
Aclarion, Inc. (NASDAQ: ACON, ACONW) announced its Nociscan solution will be used in the LIFEHAB trial in Norway to evaluate diagnosis and treatment of chronic low back pain. The trial compares lumbar interbody fusion surgery with multidisciplinary rehabilitation and aims to begin enrollment in Q2 2024. Nociscan, a SaaS platform, helps physicians identify the source of low back pain by quantifying chemical biomarkers. This marks an important step towards achieving successful reimbursement in Norway's single-payer health system.
April 25, 2024 | 1:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclarion's involvement in the LIFEHAB trial with its Nociscan solution could enhance its market position and potentially lead to successful reimbursement in Norway's healthcare system.
Aclarion's Nociscan being selected for the LIFEHAB trial signifies recognition of its technology's potential in diagnosing and treating chronic low back pain. This involvement could lead to increased visibility and credibility in the healthcare sector, especially if the trial results are positive and lead to successful reimbursement in Norway's healthcare system. Positive trial outcomes could also signal broader adoption potential in similar healthcare systems globally.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 90